Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A

Biochemical Pharmacology

Volumn 85, Issue 8, 2013, Pages 1091-1103

  Prosser, Gareth A ^a   Copp, Janine N ^a   Mowday, Alexandra M ^b   Guise, Christopher P ^b   Syddall, Sophie P ^b   Williams, Elsie M ^a   Horvat, Claire N ^a   Swe, Pearl M ^a   Ashoorzadeh, Amir ^b,c   Denny, William A ^b,c   Smaill, Jeff B ^b,c   Patterson, Adam V ^b,c   Ackerley, David F ^a,c  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

CB1954; Gene therapy; Nitroaromatic prodrug; Nitroreductase; PR 104; SOS chromotest

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATIC NITRO COMPOUND; NITROREDUCTASE; OXIDOREDUCTASE; PR 104A; PRODRUG; TRETAZICAR; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GENE; CANCER CELL CULTURE; CATALYSIS; COLON CARCINOMA; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; ESCHERICHIA COLI; GENE DIRECTED ENZYME PRODRUG THERAPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; PRIORITY JOURNAL; PROTEIN PURIFICATION;

ANTINEOPLASTIC AGENTS; AZIRIDINES; ESCHERICHIA COLI; GENE LIBRARY; GENETIC THERAPY; HCT116 CELLS; HUMANS; NITROGEN MUSTARD COMPOUNDS; NITROREDUCTASES; PRODRUGS; SOS RESPONSE (GENETICS);

EID: 84875225632     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.01.029     Document Type: Article

References (43)

1. N. Schellmann, P.M. Deckert, D. Bachran, H. Fuchs, and C. Bachran Targeted enzyme prodrug therapies Mini Rev Med Chem 10 2010 887 904
2. W.A. Denny Prodrug strategies in cancer therapy Eur J Med Chem 36 2001 577 595
3. T.C. Liu, and D. Kirn Gene therapy progress and prospects: oncolytic viruses Gene Ther 15 2008 877 884
4. N.S. Forbes Engineering the perfect (bacterial) cancer therapy Nat Rev Cancer 10 2010 785 794
5. G.U. Dachs, M.A. Hunt, S. Syddall, D.C. Singleton, and A.V. Patterson Bystander or no bystander for gene directed enzyme prodrug therapy Molecules 14 2009 4517 4545
6. N.G. Rainov A phase III clinical evaluation of HSV thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme Hum Gene Ther 11 2000 2389 2401
7. N.L. Brown, and N.R. Lemoine Clinical trials with GDEPT: cytosine deaminase and 5-fluorocytosine Methods Mol Med 90 2004 451 457
8. A.V. Patterson, M.P. Saunders, and O. Greco Prodrugs in genetic chemoradiotherapy Curr Pharm Des 9 2003 2131 2154
9. G. Chung-Faye, D. Palmer, D. Anderson, J. Clark, M. Downes, and J. Baddeley Virus-directed enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954 Clin Cancer Res 7 2001 2662 2668
10. G.J. Atwell, M. Boyd, B.D. Palmer, R.F. Anderson, S.M. Pullen, and W.R. Wilson Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis (2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase Anticancer Drug Des 11 1996 553 567
11. P. Patel, J.G. Young, V. Mautner, D. Ashdown, S. Bonney, and R.G. Pineda A phase I/II clinical trial in localized prostate cancer of adenovirus expressing nitroreductase with CB1954 Mol Ther 17 2009 1292 1299
12. M.B. Jameson, D. Rischin, M. Pegram, J. Gutheil, A.V. Patterson, and W.A. Denny A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors Cancer Chemother Pharmacol 65 2010 791 801
13. M.J. McKeage, Y. Gu, W.R. Wilson, A. Hill, K. Amies, and T.J. Melink A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients BMC Cancer 11 2011 432
14. G.M. Anlezark, R.G. Melton, R.F. Sherwood, B. Coles, F. Friedlos, and R.J. Knox The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitroreductase enzyme from Escherichia coli-a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT) Biochem Pharmacol 44 1992 2289 2295
15. G.A. Prosser, A.V. Patterson, and D.F. Ackerley uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954 J Biotechnol 150 2010 190 194
16. C.D. Emptage, R.J. Knox, M.J. Danson, and D.W. Hough Nitroreductase from Bacillus licheniformis: a stable enzyme for prodrug activation Biochem Pharmacol 77 2009 21 29
17. J. Theys, O. Pennington, L. Dubois, G. Anlezark, T. Vaughan, and A. Mengesha Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo Br J Cancer 95 2006 1212 1219
18. P.M. Swe, J.N. Copp, L.K. Green, C.P. Guise, A.M. Mowday, and J.B. Smaill Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954 Biochem Pharmacol 84 2012 775 783
19. G.A. Prosser, J.N. Copp, S.P. Syddall, E.M. Williams, J.B. Smaill, and W.R. Wilson Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954 Biochem Pharmacol 79 2010 678 687
20. S.O. Vass, D. Jarrom, W.R. Wilson, E.I. Hyde, and P.F. Searle E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954 Br J Cancer 100 2009 1903 1911
21. Y. Barak, S.H. Thorne, D.F. Ackerley, S.V. Lynch, C.H. Contag, and A. Matin New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution Mol Cancer Ther 5 2006 97 103
22. Y. Barak, Y. Nov, D.F. Ackerley, and A. Matin Enzyme improvement in the absence of structural knowledge: a novel statistical approach ISME J 2 2008 171 179
23. Y. Jiang, J. Han, C. Yu, S.O. Vass, P.F. Searle, and P. Browne Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation J Med Chem 13 2006 4333 4343
24. D.C. Singleton, D. Li, S.Y. Bai, S.P. Syddall, J.B. Smaill, and Y. Shen The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR) Cancer Gene Ther 14 2007 953 967
25. G.J. Atwell, S. Yang, F.B. Pruijn, S.M. Pullen, A. Hogg, and A.V. Patterson Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy J Med Chem 50 2007 1197 1212
26. S.C. Liu, G.O. Ahn, M. Kioi, M.J. Dorie, A.V. Patterson, and J.M. Brown Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104 Cancer Res 68 2008 7995 8003
27. G.M. Anlezark, T. Vaughan, E. Fashola-Stone, N.P. Michael, H. Murdoch, and M.A. Sims Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954 Microbiology 148 2002 297 306
28. R.J. Knox, M.P. Boland, F. Friedlos, B. Coles, C. Southan, and J.J. Roberts The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4- hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2) Biochem Pharmacol 37 1988 4671 4677
29. K.A. Datsenko, and B.L. Wanner One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products Proc Natl Acad Sci U S A 97 2000 6640 6645
30. P.R. Race, A.L. Lovering, S.A. White, J.I. Grove, P.F. Searle, and C.W. Wrighton Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954 J Mol Biol 368 2007 481 492
31. A.V. Patterson, D.M. Ferry, S.J. Edmunds, Y. Gu, R.S. Singleton, and K. Patel Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104 Clin Cancer Res 13 2007 3922 3932
32. S. Hobbs, S. Jitrapakdee, and J.C. Wallace Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins Biochem Biophys Res Commun 252 1998 368 372
33. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, and D. Vistica New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 1990 1107 1112
34. V. Koronakis, J. Eswaran, and C. Hughes Structure and function of TolC: the bacterial exit duct for proteins and drugs Annu Rev Biochem 73 2004 467 489
35. Y. Davidov, R. Rozen, D.R. Smulski, T.K. Van Dyk, A.C. Vollmer, and D.A. Elsemore Improved bacterial SOS promoter::lux fusions for genotoxicity detection Mutat Res 466 2000 97 107
36. E. Shapiro, and F. Baneyx Stress-based identification and classification of antibacterial agents: second-generation Escherichia coli reporter strains and optimization of detection Antimicrob Agents Chemother 46 2002 2490 2497
37. B.D. Palmer, P. van Zijl, W.A. Denny, and W.R. Wilson Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4- dinitrobenzamide J Med Chem 38 1995 1229 1241
38. D. Jarrom, M. Jaberipour, C.P. Guise, S. Daff, S.A. White, and P.F. Searle Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954 Biochemistry 48 2009 7665 7672
39. M. Jaberipour, S.O. Vass, C.P. Guise, J.I. Grove, R.J. Knox, and L. Hu Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations Biochem Pharmacol 79 2010 102 111
40. C.P. Guise, M.R. Abbattista, S.R. Tipparaju, N.K. Lambie, J. Su, and D. Li Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia Mol Pharmacol 81 2012 31 40
41. C.P. Guise, M.R. Abbattista, R.S. Singleton, S.D. Holford, J. Connolly, and G.U. Dachs The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3 Cancer Res 70 2010 1573 1584
42. J.J. Lavinder, S.B. Hari, B.J. Sullivan, and T.J. Magliery High-throughput thermal scanning: a general, rapid dye-binding thermal shift screen for protein engineering J Am Chem Soc 131 2009 3794 3795
43. Robins KJ, Hooks DO, Rehm BHA, Ackerley DF. Escherichia coli NemA is an efficient chromate reductase that can be biologically immobilized to provide a cell free system for remediation of hexavalent chromium. PLoS ONE, http://dx.doi.org/10.1371/journal.pone.0059200, in press.